Search 

Adjuvant Therapeutics Inc. is a clinical stage medical device company that is developing a system to improve the effectiveness of radiotherapy for cancer treatment. The system, called OncO2™, uses innovative technology to increase oxygen concentrations in tumours, making them more sensitive to radiation.

Poor tumour oxygen has long been known to make radiation less effective, particularly in cancers of the head and neck, where 5 year survival rates range from 17% to about 63%. The OncO2™ system allows for individual optimization of therapy to maximize the effectiveness of the radiation.

Adjuvant Therapeutics will initially focus on head and neck cancers, however the OncO2™ system can also address other types of resistant cancers such as those of the cervix and bladder.

The Advanced Medical Technology Association (AdvaMed), is a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. AdvaMed represents 80 percent of medical technology firms in the United States and acts as the common voice for companies producing medical devices, diagnostic products and health information systems. AdvaMed members produce nearly 90 percent of the health care technology purchased annually in the United States and more than 40 percent purchased annually around the world. AdvaMed's member companies range from the largest to the smallest medical technology innovators and companies.

AdvaMed 2015 - October 5-7, San Diego - is the leading MedTech Conference in North America, bringing more than 1,000 companies together in a uniquely multifaceted environment for business development, capital formation, innovative technology showcasing, world-class educational opportunities and networking. An event rich in international flavor and featuring a deep, diverse attendee list that includes influential policy-makers, business executives and media, AdvaMed 2015 seeks to advance industry discussion from key perspectives through detailed panel sessions, executive forums and more. It is a “must-attend” event for any MedTech company.

AdVax is an inter/multi-disciplinary team of individuals who have developed major paradigm-shifting science, research, technology and new clinical data sets demonstrating previously unidentified bacterial infections are able to translocate to the brain and be linked to the induction of Alzheimer’s disease.

We have developed novel and proprietary real time molecular diagnostics to identify these non-culturable bacteria and then apply novel immune refocusing technologies to create both monoclonal antibodies that could be used in treatments and a first of its kind vaccine for the prevention of both cardiovascular and Alzheimer’s disease.

Our program is well on its way to identifying the major disease-inducing bacteria, which are then ready to be put into the immune refocusing technology for the derivation of human monoclonal antibodies and vaccines.

Advent Life Sciences

We invest predominantly in early and mid-stage life sciences companies.  We seek to back truly innovative companies that have a first-in-class or best-in-class approach and who are looking for a well-connected partner on the road to success.

Our investments cover a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics.Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. We are a deliberately small, and highly focused team of senior individuals, with long-standing track records of entrepreneurial and investment success across the UK, Europe and the USA.

Real people. Real insight. Real value.

Innovation. Clarity. Execution.

ALIAD is the venture capital subsidiary of the Air Liquide Group (L'Air Liquide S.A.), one of the largest multinational providers of industrial and medical gases and related activities, headquartered in Paris, France. The healthcare division of the Air Liquide Group has been playing a significant role in healthcare with over €2 billion in revenue. 
ALIAD aims to promote the Group’s growth and access to innovations through taking minority stakes in innovative technology start-ups outside the Group. ALIAD can lead or co-invest with other investors. Typical allocations are made in equity and range from €1-10 million. ALIAD is currently seeking new opportunities across a wide geography, including Western Europe, North and South America and Asia.

Allurion Technologies was founded in 2009 to develop an intragastric balloon for weight loss that can be administered without surgery, endoscopy, or anesthesia. Obesity is a worldwide epidemic, yet only 2% of patients who qualify for bariatric surgery go on to be treated. Several endoscopic weight loss techniques are under development for the overweight and obese population, but they are restricted to the gastroenterologist call point and more expensive due to the costs associated with endoscopy and anesthesia.

Allurion's Elipse intragastric balloon is swallowed and excreted and can be delivered without endoscopy or anesthesia, thereby making it accessible to non-endoscopists and to consumers at a lower price point.

Allurion is currently a clinical-stage company seeking funds for further clinical work and OUS commercialization.

Altravax is a privately held biopharmaceutical company focused on developing first-in-class biological products to fight infectious diseases or treat other indications. The Company has a robust pipeline of candidates at various preclinical stages of development including a therapeutic vaccine against chronic hepatitis B infection. Altravax seeks investment opportunities to develop these lead candidates for clinical testing.